BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Alliance Pharmaceutical Corp. (ALLP) Updates Oxygent(TM) Clinical Development Plan


11/21/2007 12:44:51 PM

SAN DIEGO, Nov. 21 /PRNewswire-FirstCall/ -- Alliance Pharmaceutical Corp. . Following a Steering Committee meeting last week in China with its partner Beijing Double-Crane Pharmaceutical Co., Ltd. (Double-Crane), Alliance has updated its clinical development plan for Oxygent(TM) (perfluorochemical [PFC] emulsion) to focus primarily on supporting the initial clinical development of Oxygent in China. The clinical development plan for China is to investigate Oxygent in maintaining hemodynamic stability during major surgery, thereby potentially reducing or avoiding intraoperative transfusions of donor blood in major surgery. In addition, the Phase 2 clinical trial in China will incorporate oxygenation endpoints of postoperative improvement of organ function, such as the gut, heart, brain and kidney. As a result, Alliance will discontinue enrollment in the current French study and evaluate a new protocol to correspond to the China Phase 2 study. Alliance is currently transferring the manufacturing technology to enable Double-Crane to manufacture Oxygent in China. Following the manufacture of clinical supplies in China, Double-Crane plans to submit an IND to the sFDA, which is anticipated to be completed in 2008. Alliance will seek additional funding to support this plan.

About Alliance Pharmaceutical Corp.

Alliance is a development-stage pharmaceutical company that is currently focused on developing its lead product, Oxygent, which is based on its proprietary PFC technology. Oxygent is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.

Except for historical information, the matters set forth in this release are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth herein. Alliance refers you to cautionary information contained in documents Alliance files with the Securities and Exchange Commission from time to time, including the last Form 10-KSB and Form 10-QSB. Alliance is under no obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

CONTACT: Alliance Pharmaceutical Corp., +1-858-410-5200



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES